Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali 3-том 2-сан (2022)
PULSE THERAPY WITH HIGH DOSES OF CORTICOSTEROIDS INCREASES THE SURVIVAL OF PATIENTS WITH COVID-19
Закирьяева Парвина Одиловна
Аннотация
Covid-19 is a disease caused by the SARS-COV-2 virus, originally described in Jun, China, in December 2019. It is postulated that 80% of the infected population do not experience any symptoms or mild symptoms, and 20% are hospitalized with 5% need intensive care, while the mortality rate in these cases is 50% [1-3]. The course of the disease is divided into three phases: the first phase is characterized by a viral infection of the respiratory tract; secondary pulmonary phase, characterized by a pulmonary infection with a non -hypoxic stage (phase IIa) and turning into a hypoxic stage (phase IIB); And the third hyper -inflammatory phase [4]. The clinical study showed that, depending on the age of the patient, individual Covid-19 phases can appear more or less virulent: while tolerance to the first virulent phase decreases with age, the last hyper-inflammatory phase can be vital. Threats younger patients. The hyper -inflammatory phase has the highest mortality rate. This hyper -inflammatory response is characterized by the outgrowth of the pro -inflammatory cytokines of the early answer, which can lead to polyorgan deficiency and death [5–7]. Due to the urgency of this pandemic, many interventions were tested in order to counteract this hyper-inflammatory reaction. Some of these interventions include drugs that block IL-6 (for example, toosymab, IL-1 (anakinra) or corticosteroids in various doses. However, the use of the latter turned out to be controversial and continues to be the subject of disputes. In this study, we study whether there is a connection between pulse therapy with corticosteroids in high doses (GKS) and a decrease in death risk in patients with a high level of inflammation along with other interventions. To study some diagnostic criteria that can be used to determine which patients can get the most beneficial benefits, we also analyze the differences in laboratory markers between the COVID-19 survivors throughout the course.
COVID-19, пневмония, пульс-терапия, кортикостероиды, гипервосполительная реакцияCovid-19, pneumonia, pulse therapy, corticosteroids, hyper-fit reactionCOVID-19, pnevmoniya, pulsli terapiya, kortikosteroidlar, giper yallig’lanish reaktsiyasi.
Метадайындар булагы: журналдын OAI-PMH архиви · Sindex толук текстти сактабайт, булакка шилтеме берет.